Natera (NASDAQ:NTRA) CEO Steven Leonard Chapman Sells 1,590 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 1,590 shares of the business’s stock in a transaction dated Wednesday, January 21st. The shares were sold at an average price of $235.00, for a total value of $373,650.00. Following the completion of the sale, the chief executive officer directly owned 219,150 shares of the company’s stock, valued at $51,500,250. The trade was a 0.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Steven Leonard Chapman also recently made the following trade(s):

• On Tuesday, January 20th, Steven Leonard Chapman sold 71,932 shares of Natera stock. The stock was sold at an average price of $234.74, for a total value of $16,885,317.68.
• On Friday, January 2nd, Steven Leonard Chapman sold 3,848 shares of Natera stock. The stock was sold at an average price of $229.08, for a total value of $881,499.84.
• On Monday, December 1st, Steven Leonard Chapman sold 4,400 shares of Natera stock. The shares were sold at an average price of $238.07, for a total value of $1,047,508.00.
• On Monday, November 3rd, Steven Leonard Chapman sold 160,703 shares of Natera stock. The stock was sold at an average price of $199.96, for a total transaction of $32,134,171.88.
• On Tuesday, October 28th, Steven Leonard Chapman sold 3,680 shares of Natera stock. The shares were sold at an average price of $191.46, for a total transaction of $704,572.80.
• On Monday, October 27th, Steven Leonard Chapman sold 2,335 shares of Natera stock. The shares were sold at an average price of $192.32, for a total transaction of $449,067.20.

Natera Price Performance

Shares of NASDAQ:NTRA opened at $242.91 on Friday. Natera, Inc. has a 1-year low of $125.38 and a 1-year high of $256.36. The stock has a market cap of $33.60 billion, a P/E ratio of -106.07 and a beta of 1.62. The firm has a fifty day moving average price of $233.44 and a 200 day moving average price of $190.60.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The business had revenue of $592.18 million during the quarter, compared to analyst estimates of $514.55 million. During the same quarter in the prior year, the firm posted ($0.26) earnings per share. The company’s revenue for the quarter was up 34.7% compared to the same quarter last year. Sell-side analysts expect that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Hedge Funds Weigh In On Natera

Large investors have recently made changes to their positions in the stock. Ritholtz Wealth Management purchased a new stake in Natera during the fourth quarter worth about $496,000. Massachusetts Financial Services Co. MA increased its holdings in Natera by 1.0% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 2,047,963 shares of the medical research company’s stock valued at $469,168,000 after buying an additional 20,927 shares in the last quarter. Apollon Wealth Management LLC acquired a new stake in shares of Natera during the 4th quarter valued at approximately $452,000. DDD Partners LLC boosted its stake in shares of Natera by 12.3% during the 4th quarter. DDD Partners LLC now owns 1,748 shares of the medical research company’s stock worth $400,000 after acquiring an additional 192 shares in the last quarter. Finally, Jackson Thornton Wealth Management LLC grew its holdings in shares of Natera by 8.8% in the 4th quarter. Jackson Thornton Wealth Management LLC now owns 2,838 shares of the medical research company’s stock worth $706,000 after acquiring an additional 230 shares during the period. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have weighed in on NTRA. Guggenheim lifted their target price on Natera from $230.00 to $270.00 and gave the company a “buy” rating in a research note on Monday, January 5th. Morgan Stanley upped their price objective on shares of Natera from $220.00 to $265.00 and gave the stock an “overweight” rating in a research report on Monday, December 1st. UBS Group raised their target price on shares of Natera from $218.00 to $280.00 and gave the stock a “buy” rating in a research note on Tuesday, November 18th. JPMorgan Chase & Co. boosted their price target on shares of Natera from $250.00 to $260.00 and gave the stock an “overweight” rating in a research note on Monday, December 15th. Finally, Wells Fargo & Company increased their price target on shares of Natera from $190.00 to $205.00 and gave the stock an “equal weight” rating in a report on Monday, December 15th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $245.50.

Trending Headlines about Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera published peer‑reviewed clinical validation of its Latitude™ tissue‑free MRD test for colorectal cancer in npj Precision Oncology — a data milestone that strengthens clinical credibility and could accelerate adoption of a high‑value diagnostic product. Natera Publishes Clinical Validation of Latitude™ Tissue-Free MRD Test in Colorectal Cancer
• Negative Sentiment: CEO Steven Leonard Chapman sold a material block of shares (71,932 shares on Jan 20 and additional smaller sales on Jan 21), reducing his stake by roughly 24.9% from prior levels — a large, high‑profile insider sale that may be viewed negatively by the market. CEO Form 4
• Negative Sentiment: CFO Michael Burkes Brophy disclosed substantial sales (23,948 and 37,175 shares across Jan 20–21), cutting his ownership materially (~36.7% decrease on later filing) — another large insider liquidation that can weigh on near‑term sentiment. CFO Form 4
• Negative Sentiment: Other insiders (John Fesko and Solomon Moshkevich) also sold shares on Jan 20–21 (multiple transactions totaling tens of thousands of shares combined), modestly reducing their stakes. These coordinated/clustered sales increase perceived supply risk. Insider Form 4 example

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.